echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Breakthrough itch therapy submits new drug applications for priority review

    Breakthrough itch therapy submits new drug applications for priority review

    • Last Update: 2021-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Chronic renal disease-related itching (CKD-aP) is a stubborn, systemic itching disorder that occurs mostly in CKD patients receiving hemodialysis and peritina dialysis.
    stage III-V CKD patients who have not received dialysis treatment also have itching.
    comprehensive longitudinal multi-country study, it is estimated that about 60%-70% of dialysis patients will develop itching, of which 30% to 40% are moderate to severe itching.
    itch treatments, such as antihistamines and corticosteroids, are currently used for these patients, but they do not provide consistent and adequate relief.
    severe chronic itching can have a direct impact on the quality of life of patients, such as poor sleep quality, and may even lead to depression.
    Korsuva is a highly selective exosome opioid-sensitive excitant.
    it has strong analgesic, anti-inflammatory and anti-itching effects in both humans and animals.
    Because Korsuva performs poorly in penetrating the blood-brain barrier, it has little or no central nervous system (CNS)-mediated side effects such as nausea, vomiting, sedation, respiratory suppression, abuse, addiction, or euphoria.
    Difelikefalin Molecular Structure (Photo: Edgar 181), Public domain, via Wikimedia Commons, this NDA submission is supported by positive data from two key Phase 3 clinical trials, including the KALM-1 trial in the United States and the global KALM-2 trial, as well as support data from 32 other clinical studies.
    In the randomized double-blind, placebo-containing control group of Phase 3 clinical trial KALM-2, 54 percent of patients in the treatment group had a 24-hour daily itching intensity numeric scale (WI-NRS) score reduced by 3 points or more in the 12th week of treatment, compared with 42 percent of patients in the placebo group who reached this level, reaching the primary endpoint of the trial.
    in addition, 41 percent of patients in the treatment group had WI-NRS scores that improved by 4 points or more compared to the baseline, and only 28 percent of patients in the placebo group achieved this level, reaching a critical secondary endpoint of the trial.
    submission of the NDA for the Korsuva injection is an important milestone for hemodialysis patients with persistent itching.
    Derek Chalmers, President and CEO of Cara Therapeutics, said, "We look forward to continuing to work with the FDA during the review process."
    if approved, we will continue to focus on preparing for the launch of Korsuva injections with our commercial partner Vifor Pharma.
    : This article is intended to introduce medical and health research, not treatment options recommended.
    if you need guidance on treatment options, visit a regular hospital.
    : s1. Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus. Retrieved December 28, 2020, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.